[go: up one dir, main page]

WO2009057664A1 - 抗体及びその利用 - Google Patents

抗体及びその利用 Download PDF

Info

Publication number
WO2009057664A1
WO2009057664A1 PCT/JP2008/069696 JP2008069696W WO2009057664A1 WO 2009057664 A1 WO2009057664 A1 WO 2009057664A1 JP 2008069696 W JP2008069696 W JP 2008069696W WO 2009057664 A1 WO2009057664 A1 WO 2009057664A1
Authority
WO
WIPO (PCT)
Prior art keywords
reactivity
antibody
amyloid
amylospheroid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/069696
Other languages
English (en)
French (fr)
Inventor
Minako Hoshi
Michio Sato
Shoji Ideno
Koji Naito
Satoshi Horie
Munehiro Noda
Hajime Horii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Chemical Corp
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp, Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Chemical Corp
Priority to CN200880113862.8A priority Critical patent/CN101878301B/zh
Priority to US12/734,359 priority patent/US8445649B2/en
Priority to EP08844261.1A priority patent/EP2224000B1/en
Priority to HK11104163.0A priority patent/HK1150061B/xx
Priority to JP2009539096A priority patent/JP5185946B2/ja
Publication of WO2009057664A1 publication Critical patent/WO2009057664A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　本発明は、アミロイド前駆蛋白質に対する反応性が低く、かつアミロスフェロイドに対する反応性が、アミロイドβ線維またはアミロイドβモノマー蛋白質に対する反応性よりも高い抗体等を提供することを目的とする。本発明によれば、アミロスフェロイドに対する反応性が、アミロイド前駆蛋白質に対する反応性よりも高く、かつ以下の何れか１以上の特徴を有する抗体が提供される。（i）アミロスフェロイドに対する反応性が、アミロイドβ線維に対する反応性よりも高い；（ii）アミロスフェロイドに対する反応性が、アミロイドβモノマー蛋白質に対する反応性よりも高い；（iii）アミロスフェロイドによる神経細胞死誘導に対する阻害活性を有する。
PCT/JP2008/069696 2007-10-29 2008-10-29 抗体及びその利用 Ceased WO2009057664A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CN200880113862.8A CN101878301B (zh) 2007-10-29 2008-10-29 抗体及其应用
US12/734,359 US8445649B2 (en) 2007-10-29 2008-10-29 Antibody and use thereof
EP08844261.1A EP2224000B1 (en) 2007-10-29 2008-10-29 Antibody and use thereof
HK11104163.0A HK1150061B (en) 2007-10-29 2008-10-29 Antibody and use thereof
JP2009539096A JP5185946B2 (ja) 2007-10-29 2008-10-29 抗体及びその利用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007280187 2007-10-29
JP2007-280187 2007-10-29

Publications (1)

Publication Number Publication Date
WO2009057664A1 true WO2009057664A1 (ja) 2009-05-07

Family

ID=40591051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/069696 Ceased WO2009057664A1 (ja) 2007-10-29 2008-10-29 抗体及びその利用

Country Status (5)

Country Link
US (1) US8445649B2 (ja)
EP (1) EP2224000B1 (ja)
JP (3) JP5185946B2 (ja)
CN (2) CN104098695B (ja)
WO (1) WO2009057664A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013523182A (ja) * 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2013094614A1 (ja) 2011-12-22 2013-06-27 Ｔａｏヘルスライフファーマ株式会社 合成アミロスフェロイドの製造方法
WO2013099806A1 (ja) 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
WO2015111430A1 (ja) * 2014-01-21 2015-07-30 株式会社 島津製作所 Ａｐｐ切断型ペプチドの測定方法
JP2015536645A (ja) * 2012-10-15 2015-12-24 メディミューン リミテッド アミロイドβに対する抗体
JP2019038806A (ja) * 2011-12-29 2019-03-14 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
JPWO2021100744A1 (ja) * 2019-11-19 2021-05-27
CN114478762A (zh) * 2022-02-15 2022-05-13 武汉天德生物科技有限公司 一种β-淀粉样多肽1-42单克隆抗体、ELISA试剂盒及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012104824A1 (en) * 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
JP7161401B2 (ja) * 2016-04-14 2022-10-26 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
CA3185040A1 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2912618B2 (ja) 1986-03-27 1999-06-28 メディカル リサーチ カウンスル 組換えｄｎａ生産物及び製造法
JP2001247600A (ja) 2000-03-09 2001-09-11 Mitsubishi Chemicals Corp 高い毒性を有するアミロイドβ蛋白質の調製方法
JP2002105099A (ja) 2000-09-28 2002-04-10 Mitsubishi Chemicals Corp 自己会合型アミロイドβ蛋白質
US20030165496A1 (en) 2000-12-06 2003-09-04 Elan Pharmaceuticals, Inc. Humanized antibodies that recognize beta amyloid peptide
WO2006016644A1 (ja) 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation 抗体及びその利用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
ES2437875T3 (es) 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide
CA2501091A1 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
CN1849139A (zh) * 2002-10-09 2006-10-18 里纳特神经系统学公司 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
WO2006046644A1 (ja) * 2004-10-28 2006-05-04 Sanko Junyaku Co., Ltd. アルツハイマー病の検定方法及び診断試薬
CN101555477B (zh) * 2009-04-22 2011-04-20 北京交通大学 抗人淀粉样蛋白单克隆抗体重轻链可变区基因及其应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2912618B2 (ja) 1986-03-27 1999-06-28 メディカル リサーチ カウンスル 組換えｄｎａ生産物及び製造法
JP2001247600A (ja) 2000-03-09 2001-09-11 Mitsubishi Chemicals Corp 高い毒性を有するアミロイドβ蛋白質の調製方法
JP2002105099A (ja) 2000-09-28 2002-04-10 Mitsubishi Chemicals Corp 自己会合型アミロイドβ蛋白質
US20030165496A1 (en) 2000-12-06 2003-09-04 Elan Pharmaceuticals, Inc. Humanized antibodies that recognize beta amyloid peptide
WO2006016644A1 (ja) 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation 抗体及びその利用

Non-Patent Citations (30)

* Cited by examiner, † Cited by third party
Title
ANKARCRONA, M. ET AL., NEURON, vol. 15, 1995, pages 961
G. KOHLER; C. MILSTEIN, NATURE, vol. 256, 1975, pages 495
GLENNER, G. G.; WONG, C. W., BIOCHEM. BIOPHYS. RES. COMMUN., vol. 120, no. 3, 1984, pages 885 - 890
GRUNDKE-IQBAL, I. ET AL., PROC. NATL ACAD. SCI. USA, vol. 83, 1986, pages 4913 - 4917
GRUNDKE-IQBAL, I. ET AL., PROC. NATL. ACAD. SCI. U.SA, vol. 83, 1986, pages 4913 - 4917
HOSHI, M. ET AL., PROC. NATL. ACAD. SCI. U.SA, vol. 100, 2003, pages 6370 - 6375
HOSHI, M. ET AL., PROC. NATL. ACAD. SCI. U.SA, vol. 93, 1996, pages 2719 - 2723
HOSHI, M., PROC. NATL. ACAD. SCI. U.S.A, vol. 100, 2003, pages 6370 - 6375
HOSHI,M. ET AL.: "Spherical aggregates of beta- amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3beta", PROC NATL ACAD SCI U S A, vol. 100, no. 11, 2003, pages 6370 - 6375, XP008135984 *
IHARA, Y ET AL., J. BIOCHEM., vol. 99, 1986, pages 1807 - 1810
IHARA, Y ET AL., J.BIOCHEM., vol. 99, 1986, pages 1807 - 1810
JONES ET AL., NATURE, vol. 321, 1986, pages 522
LORENZO, A ET AL., PROC. NATL ACAD. SCI. U.SA, vol. 91, 1994, pages 12243 - 12247
LORENZO, A.; YANKNER, B. A., PROC. NATL. ACAD. SCI. U.S.A., vol. 91, 1994, pages 12243 - 12247
LORENZO, A; YANKNERB. A, PROC. NATL. ACAD. SCI. USA, vol. 91, 1994, pages 12243 - 12247
MINAKO HOSHI: "beta-amyloid Jiko Soshikika ni yoru Shinkei Dokusei no Hatsugen", KAGAKU TO KOGYO, vol. 57, no. 5, May 2004 (2004-05-01), pages 519 - 521, XP002999357 *
MINAKO HOSHI: "'Katachi' ga Seigyo suru Shinkei no Shi", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 49, no. 7, May 2004 (2004-05-01), pages 1098 - 1100, XP002999355 *
MOSSMAN, T, J. IMMUNOL. METHODS, vol. 65, 1983, pages 55
NAKAMURA ET AL., NUCLECIC ACID RES, vol. 29, 2000, pages 292
PROC. NATL. ACAD. SCI. USA, vol. 100, 2003, pages 6370 - 6375
QUEEN ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 2869
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323
SCHUBERT, D. ET AL., NATURE, vol. 249, no. 454, 1974, pages 224 - 227
SCIENCE, vol. 274, no. 5284, 4 October 1996 (1996-10-04), pages 99 - 102
SELKOE, D. J., ANNU. REV NEUROSCI., vol. 12, 1989, pages 463 - 490
SELKOE, D.J., ANNU. REV NEUROSCI., vol. 12, 1989, pages 463 - 490
VERHOEYEN ET AL., SCIENCE, vol. 239, 1988, pages 1534
WOO, K B.; FUNKHOUSER, W K.; SULLIVAN, C.; ALABASTER, 0., CELL TISSUE KINET., vol. 13, no. 6, 1980, pages 591 - 604
YANKNER, B. A. ET AL., SCIENCE, vol. 250, 1990, pages 279 - 282
YANKNER,B. A, SCIENCE, vol. 250, 1990, pages 279 - 282

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020103288A (ja) * 2010-04-15 2020-07-09 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2013523182A (ja) * 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP2016028030A (ja) * 2010-04-15 2016-02-25 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
JP2018058837A (ja) * 2010-04-15 2018-04-12 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
WO2013094614A1 (ja) 2011-12-22 2013-06-27 Ｔａｏヘルスライフファーマ株式会社 合成アミロスフェロイドの製造方法
US8946327B2 (en) 2011-12-22 2015-02-03 Tao Health Life Pharma Co., Ltd. Method for producing synthetic amylospheroid
JPWO2013099806A1 (ja) * 2011-12-29 2015-05-07 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
JP2015214557A (ja) * 2011-12-29 2015-12-03 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
US9751912B2 (en) 2011-12-29 2017-09-05 Tao Health Life Pharma Co., Ltd. Neurotoxic target for amylospheroid, method and material for reducing the neurotoxicity of amylospheroid, and use thereof
KR20160075836A (ko) 2011-12-29 2016-06-29 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
JP2018058838A (ja) * 2011-12-29 2018-04-12 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
CN110075111A (zh) * 2011-12-29 2019-08-02 道健康生活医药株式会社 针对淀粉样蛋白球体发生竞争阻断的物质的用途及候补化合物的筛选方法
WO2013099806A1 (ja) 2011-12-29 2013-07-04 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
JP2019038806A (ja) * 2011-12-29 2019-03-14 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
US12344664B2 (en) 2012-10-15 2025-07-01 Medimmune Limited Antibodies to amyloid beta
JP2023116770A (ja) * 2012-10-15 2023-08-22 メディミューン リミテッド アミロイドβに対する抗体
JP2018150346A (ja) * 2012-10-15 2018-09-27 メディミューン リミテッド アミロイドβに対する抗体
JP2020099340A (ja) * 2012-10-15 2020-07-02 メディミューン リミテッド アミロイドβに対する抗体
JP2015536645A (ja) * 2012-10-15 2015-12-24 メディミューン リミテッド アミロイドβに対する抗体
US10942190B2 (en) 2014-01-21 2021-03-09 Shimadzu Corporation Measurement method for amyloid precursor protein cleavage peptides
JPWO2015111430A1 (ja) * 2014-01-21 2017-03-23 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
WO2015111430A1 (ja) * 2014-01-21 2015-07-30 株式会社 島津製作所 Ａｐｐ切断型ペプチドの測定方法
JPWO2021100744A1 (ja) * 2019-11-19 2021-05-27
WO2021100744A1 (ja) 2019-11-19 2021-05-27 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ＡＳＰＤ）の代替物となりうるアミロイドβタンパク質（Ａβ）の架橋体、及びＡＳＰＤの分析
JP7383043B2 (ja) 2019-11-19 2023-11-17 公益財団法人神戸医療産業都市推進機構 アミロスフェロイド（ＡＳＰＤ）の代替物となりうるアミロイドβタンパク質（Ａβ）の架橋体、及びＡＳＰＤの分析
CN114478762A (zh) * 2022-02-15 2022-05-13 武汉天德生物科技有限公司 一种β-淀粉样多肽1-42单克隆抗体、ELISA试剂盒及其应用
CN114478762B (zh) * 2022-02-15 2024-06-04 武汉天德生物科技有限公司 一种β-淀粉样多肽1-42单克隆抗体、ELISA试剂盒及其应用

Also Published As

Publication number Publication date
CN101878301A (zh) 2010-11-03
JP6128535B2 (ja) 2017-05-17
US20100297662A1 (en) 2010-11-25
JP2013135667A (ja) 2013-07-11
JP2015221796A (ja) 2015-12-10
EP2224000A1 (en) 2010-09-01
CN104098695A (zh) 2014-10-15
JP5185946B2 (ja) 2013-04-17
JPWO2009057664A1 (ja) 2011-03-10
EP2224000B1 (en) 2020-05-13
US8445649B2 (en) 2013-05-21
CN101878301B (zh) 2014-08-20
CN104098695B (zh) 2018-09-07
HK1203206A1 (en) 2015-10-23
HK1150061A1 (en) 2011-10-28
EP2224000A4 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
WO2009057664A1 (ja) 抗体及びその利用
NZ620326A (en) Cd37 immunotherapeutic combination therapies and uses thereof
WO2009100102A3 (en) Ts23 alpha-amylase variants with altered properties
EA201101189A1 (ru) Ингибитор sglt-2, предназначенный для лечения сахарного диабета типа 1, сахарного диабета типа 2, нарушенной толерантности к глюкозе или гипергликемии
WO2012170911A3 (en) Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
WO2010008739A3 (en) Aryl gpr119 agonists and uses thereof
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
WO2010029089A3 (en) Combination therapy for the treatment of diabetes and related conditions
WO2005097825A3 (en) Bmp-7 variants with improved properties
WO2009044173A3 (en) Methods of treating cancer using notch pathway inhibitors
NZ612175A (en) Anti ccr4 antibodies and uses thereof
WO2006094292A3 (en) Thienopyridine compounds, and methods of use thereof
WO2012087655A3 (en) Computing platform with adaptive cache flush
EP4265267A3 (en) Peptides for modulating t-cell activity and uses thereof
WO2011140208A3 (en) Methods and compositions for diagnosing and treating autoimmune disorders
IL189452A0 (en) Therapy with cd4 binding peptides and radiation
NZ602317A (en) Stabilized alpha-galactosidase and uses thereof
EA200870515A1 (ru) Моноциклические гетероарильные соединения
WO2011116026A3 (en) Inhibitors of beta integrin-g protein alpha subunit binding interactions
WO2007062028A3 (en) Treatment of qt interval prolongation and diseases associated therewith
WO2009048980A3 (en) Emp2 antibodies and their therapeutic uses
NZ602515A (en) Proteins that bind pi16 and uses thereof
WO2006120030A8 (en) Erythropoietin variants
ATE445406T1 (de) Verwendung von eisen(iii)-komplexverbindungen

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880113862.8

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08844261

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009539096

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008844261

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12734359

Country of ref document: US